Associate Director General, Neurological Mission, MUHC
Dr. Rouleau comes from the Université de Montréal, where he was Director of the CHU Ste-Justine Research Centre and founder and Director of the Centre of Excellence in Neuroscience. There he held the Canada Research Chair in Genetics of the Nervous System as well as the Jeanne-et-J.-Louis-Levesque Chair in Genetics of Brain Diseases. He is Director of the Réseau de Médecine Génétique Appliquée – Fonds de recherche du Québec - Santé.
He obtained his MD (Magna Cum Laude) in 1980 from the University of Ottawa and his PhD in Genetics at Harvard University in 1989. His post-graduate research in neuroscience was conducted at the Montreal Neurological Institute and at Massachusetts General Hospital. Dr. Rouleau conducted his clinical training in internal medicine at the Montreal General Hospital, neurology residency at the Montreal Neurological Institute, and research fellowship at the Massachusetts General Hospital.
His landmark achievements are his contributions to the identification of over 20 disease-causing genes and his discovery of new mutational mechanisms. Over the last 20 years, Dr. Rouleau and his team have focused on understanding the genetic basis for diseases and identifying genes causing neurological and psychiatric diseases including amyotrophic lateral sclerosis, stroke, Essential Tremor, familial aneurysms, cavernous angiomas, epilepsy, spinocerebellar ataxia, spastic paraplegia, autism, Tourette syndrome, restless legs syndrome, schizophrenia and bipolar disorder. He has published more than 500 articles in top peer-reviewed journals such as The Lancet, Cell, and Nature, as well as 40 review articles and book chapters. His work has been cited over 26,000 times. He has delivered more than 120 lectures around the world. He has supervised many students (9 Master’s, 40 PhD, and 40 post-doctoral fellows). Many of his former students are now professors at universities in Brazil, France, Portugal, Japan, the USA and Canada.
He has received numerous awards, most recently the 2012 Prix du Québec – Prix Wilder Penfield, the Margolese National Brain Disorders Prize from the University of British Columbia, and the Henry Friesen Prize from the Royal College of Physicians and Surgeons of Canada / The Canadian Society for Clinical Investigation. He is an Officer of the Ordre national du Québec.
Dr. Rouleau sits on the editorial boards of major scientific journals including Neurology of Disease and Annals of Human Genetics, and performs ad hoc reviews for more than 25 journals. He also serves on several international scientific boards including the IGBMC Strategic Scientific Advisory Board, Strasbourg, France and is a board member of several foundations and societies dedicated to finding cures for nervous system diseases, including the Jumelles Coudé foundation, Ataxia of Charlevoix-Saguenay Foundation, Gairdner Medical Advisory Board, the Cole Foundation and the Canadian Academy of Health Sciences.
He has also served on the panel for numerous grant committees (ex. CIHR, NIH, ALSA, ENR, NNFF, FRQS). He has founded and directed several successful companies including RGS Genome Inc., Xenon Genetics Research Inc., and Emerillon Therapeutics Inc.